Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease

Collagenase clostridium histolyticum (CCH) is approved for the treatment of Peyronie's disease (PD). To date, no post-release study has evaluated patient perceived outcomes and satisfaction. Therefore, we sought to evaluate patient perceived experience with CCH injection for PD in a clinical practice.

From March 2014 to July 2015, 69 patients underwent one to four series of CCH injections for PD at our institution. Objective changes in penile curvature as well as patient-reported functional outcomes and patient perceived curvature improvements were evaluated.

In total, by the time of analysis, 31 patients (45%) completed four trials, 47 (68%) three trials, and 59 (86%) two trials. Patient reported improvements (percentage) in curvature increased with each series (Trial 1-14%, Trial 2-28%, Trial 3-30%, and Trial 4-37%, p

CCH reduced the need for surgery and restored penetration in the majority of patients completing four series of injections while significantly reducing the degree of objectively measured penile curvature. Subjective improvements in curvature increased with each series of CCH injections as well, and the majority of patients felt that the therapy was worthwhile.

The Journal of urology. 2015 Oct 14 [Epub ahead of print]

Matthew J Ziegelmann, Boyd R Viers, Kelly L McAlvany, George C Bailey, Joshua B Savage, Landon W Trost

Department of Urology, Mayo Clinic, Rochester, MN. , Department of Urology, Mayo Clinic, Rochester, MN. , Department of Urology, Mayo Clinic, Rochester, MN. , Department of Urology, Mayo Clinic, Rochester, MN. , Department of Urology, Mayo Clinic, Rochester, MN. , Department of Urology, Mayo Clinic, Rochester, MN.  

PubMed